Barclays analyst Lauren Lieberman lowered the firm’s price target on Kenvue (KVUE) to $21 from $23 and keeps an Equal Weight rating on the ...

In a report released today, Lauren Lieberman from Barclays maintained a Hold rating on Kenvue, Inc. (KVUE – Research Report), with a price ...

Kenvue Inc. closed 13.37% below its 52-week high of $24.46, which the company achieved on November 26th.

Shares of Kenvue Inc. KVUE inched 0.29% higher to $21.03 Tuesday, on what proved to be an all-around favorable trading ...

In this article, we are going to take a look at where Kenvue Inc. (NYSE:KVUE) stands against the other stocks targeted by activist hedge funds. Shareholder activism continued at a record pace in ...

We recently compiled a list of the 15 Stocks Targeted By Activist Hedge Funds. In this article, we are going to take a look at where Kenvue Inc. (NYSE:KVUE) stands against the other stocks targeted by ...

To navigate a rapidly evolving workplace landscape, Shipra Saraf, HR Head, India at Kenvue, suggests prioritise embracing digital transformation and HR technology, enhancing employee experience and ...

In this article, we are going to take a look at where Kenvue Inc. (NYSE:KVUE) stands against the other new stocks. US public markets continue to brace themselves for a 2025 resurgence, which ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Kenvue, the world’s largest pure-play consumer health company by revenue, launches its latest evidence report on the role of fluids, electrolytes and energy (FEE) in non-diarrheal illnesses which ...

A spokesperson from Kenvue, the makers of Tylenol, told Newsweek: "As a company firmly rooted in science, we support scientific discovery and exploration through research. However, we found the ...